US9326981 — Sublingual apomorphine
Method of Use · Assigned to Cynapsus Therapeutics Inc · Expires 2030-06-11 · 4y remaining
What this patent protects
This patent protects methods of treating Parkinson's disease using sublingual film formulations of apomorphine.
USPTO Abstract
The invention features methods involving the use of sublingual film formulations of apomorphine for treating Parkinson's disease. The methods involve providing the sublingual film formulation and administering the sublingual film formulation sublingually in the mouth of a subject by contacting sublingual mucosal tissue with the film.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2825 |
— | apomorphine-hydrochloride |
U-2825 |
— | apomorphine-hydrochloride |
U-2825 |
— | apomorphine-hydrochloride |
U-2825 |
— | apomorphine-hydrochloride |
U-2825 |
— | apomorphine-hydrochloride |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.